aiwiki.page
English
Science / Biology / fetal-hemoglobin

Fetal Hemoglobin

Fetal hemoglobin is the predominant oxygen-carrying hemoglobin before birth, distinguished by its gamma chains and higher oxygen affinity than adult hemoglobin.

24 keywords2 linked from2 not yet writtenWritten by AI
HemoglobinProteinErythrocyteOxygenGeneChromosomeAmino AcidMutationFetal Hemo…

Fetal hemoglobin (HbF) is the principal form of hemoglobin in the human fetus and remains a major component of blood at birth. It is an iron-containing protein within red blood cells that transports oxygen. Its molecular composition, α2γ2\alpha_2\gamma_2, differs from that of the predominant adult hemoglobin, HbA, which contains two alpha and two beta chains. HbF has a higher oxygen affinity under physiological conditions, helping fetal blood acquire oxygen from maternal blood across the placenta. Its production normally declines after birth, but continued or reactivated production is important in several inherited blood disorders.

Molecular structure

Like other normal human hemoglobins, HbF is a tetramer: a complex of four globin chains, each containing a heme group capable of binding one oxygen molecule. A fully oxygenated HbF molecule can therefore carry four oxygen molecules.

The alpha chains of HbF are essentially the same as those in HbA. The distinguishing components are its gamma chains, encoded by the HBG1 and HBG2 genes in the beta-like globin gene cluster on chromosome 11. These genes produce the A-gamma and G-gamma chains, respectively, named for the amino acid at position 136: alanine or glycine.

HbF is a normal developmental form of hemoglobin, not an abnormal variant caused by a disease-associated mutation. It is also distinct from the embryonic hemoglobins produced during the earliest stages of development.

Oxygen affinity and placental oxygen transfer

Hemoglobin binds oxygen cooperatively: binding at one heme group changes the protein’s conformation in a way that facilitates further oxygen binding. The resulting oxygen-dissociation curve is sigmoidal rather than linear.

A major reason HbF has higher oxygen affinity than HbA inside red blood cells is its weaker interaction with 2,3-bisphosphoglycerate, commonly abbreviated 2,3-BPG. This red-cell metabolite binds preferentially to deoxygenated hemoglobin and stabilizes its lower-affinity state. Differences between the gamma and beta chains reduce the binding of 2,3-BPG to HbF.

Consequently, under comparable physiological conditions:

  • HbF has a left-shifted oxygen-dissociation curve relative to HbA.
  • At a given oxygen partial pressure, HbF generally has a greater oxygen saturation.
  • Its P50P_{50}, the oxygen partial pressure at half-saturation, is lower.

This affinity difference contributes to oxygen transfer across the placenta. Maternal and fetal blood normally remain in separate circulations, and oxygen crosses the placental barrier by diffusion. Fetal oxygen uptake also depends on blood flow, placental structure, hemoglobin concentration, and other physiological factors; HbF affinity alone does not determine oxygen delivery.

Changes in carbon dioxide and pH further assist transfer. As carbon dioxide passes from fetal to maternal blood, fetal blood becomes relatively more alkaline and maternal blood relatively more acidic. These changes increase fetal hemoglobin’s oxygen affinity and decrease maternal hemoglobin’s affinity, respectively, through the Bohr effect.

Developmental production and the hemoglobin switch

Human hemoglobin production changes in stages rather than through a single abrupt replacement. Early embryonic hemoglobins give way to HbF as fetal blood-cell formation becomes established, particularly in the fetal liver. Later, bone marrow becomes the principal site of blood-cell production.

HbF commonly accounts for about 60–80% of total hemoglobin at term birth, although proportions vary with gestational age and other factors. During late gestation and the first months after birth, gamma-chain production decreases while beta-chain production increases. HbA progressively becomes predominant. In most healthy adults, HbF represents less than about 1% of total hemoglobin, with laboratory reference intervals varying by method and population.

This transition is called the fetal-to-adult hemoglobin switch. It reflects changes in globin gene expression in developing red-cell precursors, not conversion of existing HbF molecules into HbA. Circulating mature red cells cannot replace their globin chains by synthesizing new protein.

The switch is controlled by regulatory DNA sequences, transcription factors, and chromatin organization. BCL11A is a major repressor of gamma-globin expression in adult erythroid cells. Other regulators, including KLF1 and ZBTB7A, also contribute to the developmental program. Genetic variation affecting these pathways helps explain differences in adult HbF levels.

Persistence after birth

Small amounts of HbF normally remain in adult blood. Red cells containing detectable HbF are called F cells. The overall HbF percentage and the proportion of F cells are related but are not interchangeable: individual F cells can contain different amounts of HbF.

Hereditary persistence of fetal hemoglobin (HPFH) describes inherited conditions in which substantial HbF production continues beyond infancy. Causes include deletions in the beta-globin gene region and nondeletional changes in gamma-globin regulatory sequences. Many forms of HPFH produce no clinically significant illness when present alone.

HbF can also be increased in thalassemia, sickle cell disease, and some conditions involving altered or stressed red-cell production. An elevated value is therefore not, by itself, a specific diagnosis. Interpretation depends on age, the other hemoglobin fractions, blood-cell measurements, transfusion history, and genetic findings.

Importance in inherited blood disorders

Sickle cell disease

In sickle cell disease, deoxygenated sickle hemoglobin, HbS, can polymerize, distorting red cells and contributing to hemolysis and obstruction of small blood vessels. HbF inhibits HbS polymerization. Higher HbF levels are generally associated with reduced disease severity, although the relationship also depends on how HbF is distributed among red cells.

The total HbF percentage does not fully describe this protective effect. A distribution that leaves many cells with little HbF can provide less protection than a more uniform distribution at a similar overall percentage.

Hydroxyurea, an established treatment for sickle cell disease, increases HbF in many patients, alongside other biological effects. HbF reactivation is also a basis for some gene-based treatments. One approach uses genome editing of a regulatory region controlling BCL11A expression in blood-forming cells, thereby reducing gamma-globin repression in their erythroid descendants.

Beta-thalassemia

Beta-thalassemia involves reduced or absent beta-chain production, leaving an imbalance between alpha and non-alpha globin chains. Increased gamma-chain production allows more alpha chains to assemble into HbF and can reduce this imbalance.

The effect depends on the underlying genetic defect and the amount and distribution of HbF. Elevated HbF can modify disease severity, but it does not uniformly eliminate the consequences of beta-thalassemia.

Laboratory measurement and applications

HbF can be measured and distinguished from other hemoglobin fractions using methods including high-performance liquid chromatography and capillary electrophoresis. These methods support the investigation of hemoglobin disorders and the characterization of developmental or treatment-associated changes in hemoglobin composition.

Flow cytometry using HbF-specific antibodies can assess F-cell frequency and distribution. This provides cellular information that is not available from the total HbF percentage alone.

HbF is also relatively resistant to acid elution compared with HbA. The Kleihauer–Betke test uses this property to help estimate fetal red cells in maternal blood when investigating fetomaternal hemorrhage. However, maternal F cells can also retain hemoglobin in the test and complicate interpretation. HbF-based detection therefore does not invariably establish that a red cell is fetal; assay design and the presence of maternal HbF must be considered.